Clinical Trial Update: PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating PRaG regimens rechallenge in patients with resistance to PD-1/PD-L1 inhibitors in refractory advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• PRaG regimens

Snippet

Sponsor: Second Affiliated Hospital of Soochow University | Conditions: Metastatic Solid Tumor | Phase 2 | Status: UNKNOWN